2021/09/03 ALA-1000 Receive notice of patent allowance from Taiwan Intellectual Property Office (TIPO), Application No. 106131215. Post author:alarpharm Post published:7 . 9 . 2021 Post category:Media releases You Might Also Like 2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. 21 . 4 . 2022 2021/10/29 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Vietnam, Application No. 1-2019-01258. 12 . 11 . 2021 2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April. 13 . 4 . 2021 2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6 13 . 5 . 2022 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. 21 . 4 . 2022
2021/10/29 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Vietnam, Application No. 1-2019-01258. 12 . 11 . 2021
2021/04/13 -Alar Pharmaceuticals Inc., participates in American Society of Addiction Medicine (ASAM) Virtual 2021, the nation’s largest and premier conference on addiction medicine, which will hold this year between 22 – 24 April. 13 . 4 . 2021
2022/05/12 ALA-1000 Received notice of patent allowance from European Patent Office (EPO) , Application No. 17850245.6 13 . 5 . 2022
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021